OR WAIT null SECS
The investment includes an upgrade and expansion of the company’s packaging and softgel encapsulation capabilities at its facility in Aprilia, Italy.
On Oct. 4, 2018, Catalent Pharma Solutions, a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, announced that it had completed the first phase of a $7.3-million investment to upgrade and expand its packaging and softgel encapsulation capabilities at its facility in Aprilia, Italy.
The first phase of investment, completed in August 2018, saw the expansion and upgrade of the facility’s integrated packaging capabilities, and the commissioning of the first of five new softgel encapsulation lines.
The second phase of the investment will add four more encapsulation lines, which will bring the total number of lines to 23 and significantly expand production, drying, and inspection capacity for nutritional supplements and beauty softgels at the site. The company expects that these four new lines will be fully operational by January 2019.
“We have a long and proud history in softgel product development and commercial manufacturing,” said Dr. Aris Gennadios, president of Catalent Softgel Technologies, in a company press release.“This investment is driven by increasing demand for nutritional and beauty products globally and will enable Catalent to better serve these markets.”